GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tricida Inc (OTCPK:TCDAQ) » Definitions » Stock Based Compensation

Tricida (Tricida) Stock Based Compensation : $20.96 Mil (TTM As of Sep. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Tricida Stock Based Compensation?

Tricida's Stock Based Compensation for the three months ended in Sep. 2022 was $0.79 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2022 was $20.96 Mil.

Tricida Stock Based Compensation Historical Data

The historical data trend for Tricida's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tricida Stock Based Compensation Chart

Tricida Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Stock Based Compensation
Get a 7-Day Free Trial 0.88 5.15 25.17 28.30 25.88

Tricida Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.65 6.58 6.52 7.07 0.79

Tricida Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.96 Mil.

Tricida Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Tricida's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Tricida (Tricida) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tricida Inc (OTCPK:TCDAQ) » Definitions » Stock Based Compensation
Comparable Companies
CGEM AFMD GHRS IMTX IMVT OCGN YMAB AURA KPTI AMLX OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
7000 Shoreline Court, Suite 201, South San Francisco, CA, USA, 94080
Website
https://www.tricida.com
Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.
Executives
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert J Alpern director YALE SCHOOL OF MEDICINE, 333 CEDAR STREET, C203 SHM, NEW HAVEN CT 06520
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Sibling Capital Fund Ii-b L.p. 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Ii Llc 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Brian M. Isern 10 percent owner, other: *possible member of 10% group 2033 6TH AVE., SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-c L.p. 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Iii Llc 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-a L.p. 10 percent owner, other: possible member of 10% group 500 YALE AVE N, SEATTLE WA 98109
Vhcp Management Eg, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036